Drug intelligence / Profile preview

PTX-103

Development stage: Preclinical
Lead developer: Providence Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

PTX-103 is an investigational mRNA-based cancer vaccine being developed by Providence Therapeutics for the treatment of glioblastoma. The therapeutic is designed to encode a selection of common tumor antigens that are frequently expressed in glioblastoma cells. By delivering these genetic instructions, PTX-103 aims to stimulate the patient's immune system to recognize and mount a targeted anti-tumor response against the malignancy. This approach utilizes Providence's proprietary mRNA platform to potentially overcome the immunosuppressive environment associated with aggressive brain tumors. As of early 2024, the program is in the discovery and preclinical phase of development.

Beyond the preview

Go deeper on PTX-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-103.

Explore the full profile